Parallel Advisors, LLC Prothena Corp Public LTD CO Transaction History

Parallel Advisors, LLC

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$16.73 - $24.79 $485 - $718	-29 Closed	0 $0
Q2 2024 Aug 08, 2024	BUY	$19.54 - $26.15 $332 - $444	17 Added 141.67%	29 $0
Q1 2024 May 06, 2024	BUY	$24.75 - $40.66 $297 - $487	12 New	12 $0
Q4 2022 Feb 03, 2023	SELL	$52.05 - $65.0 $51,633 - $64,480	-992 Reduced 99.7%	3 $0
Q2 2022 Aug 01, 2022	SELL	$22.73 - $39.98 $68 - $119	-3 Reduced 0.3%	995 $27,000
Q1 2022 Apr 28, 2022	BUY	$30.27 - $49.22 $90 - $147	3 Added 0.3%	998 $36,000
Q3 2021 Nov 02, 2021	SELL	$48.2 - $78.89 $28,920 - $47,334	-600 Reduced 37.62%	995 $71,000
Q2 2021 Aug 06, 2021	BUY	$21.63 - $57.65 $12,978 - $34,590	600 Added 60.3%	1,595 $82,000
Q4 2020 Feb 02, 2021	SELL	$10.12 - $13.94 $1,143 - $1,575	-113 Reduced 10.2%	995 $12,000
Q2 2020 Jul 16, 2020	BUY	$9.56 - $12.51 $9,512 - $12,447	995 Added 880.53%	1,108 $11,000
Q3 2019 Nov 01, 2019	BUY	$6.89 - $10.45 $778 - $1,180	113 New	113 $1,000
Q2 2018 Jul 30, 2018	SELL	$10.99 - $44.21 $4,121 - $16,578	-375 Closed	0 $0
Q3 2017 Nov 15, 2017	BUY	$53.83 - $67.75 $20,186 - $25,406	375 New	375 $21,000
Q3 2017 Nov 14, 2017	SELL	$53.83 - $67.75 $20,186 - $25,406	-375 Closed	0 $0
Q2 2017 Aug 07, 2017	BUY	N/A	375	375 $23,000

184

42.7M

151K

102K

Ticker PRTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,922,800
Market Cap $755M
Description
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...

Get notified when there are updates to the investment portfolio of Parallel Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Parallel Advisors, LLC with notifications on news.